Drug-eluting stent in malignant biliary obstruction

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Introduction: In unresectable malignant bile duct obstruction, endoscopic stent insertion is the treatment of choice. However, the current stent allows only mechanical palliation of the obstruction, and has no anti-tumor effect. Currently, in the vascular field, the drug-eluting stent (DES) is very highly favored. Material and methods: The requirements for a DES in a non-vascular tract, such as the bile duct, are far different from those of a DES to be used in the vascular tract. The non-vascular DES must suppress tumor proliferation as well as mucosal hyperplasia. For example, the non-vascular stent might be covered with a membrane that gradually releases a chemo-agent. We do not have much experience with DES in the bile duct. Nonetheless, we are continuously testing many anti-tumor agents in animal and human studies. Conclusion: We expect and hope DES will work effectively for tumor cells in diverse ways and, more importantly, will prolong stent patency and the patients' survival periods. But considerable investigation and a clinical study of DES will be required to achieve these goals.

Original languageEnglish
Pages (from-to)628-632
Number of pages5
JournalJournal of Hepato-Biliary-Pancreatic Surgery
Volume16
Issue number5
DOIs
Publication statusPublished - 2009 Jun 25

Fingerprint

Drug-Eluting Stents
Stents
Bile Ducts
Blood Vessels
Neoplasms
Cholestasis
Hyperplasia
Membranes
Survival

All Science Journal Classification (ASJC) codes

  • Surgery
  • Hepatology

Cite this

@article{69dea230a40c47e7b1751def037b3d23,
title = "Drug-eluting stent in malignant biliary obstruction",
abstract = "Introduction: In unresectable malignant bile duct obstruction, endoscopic stent insertion is the treatment of choice. However, the current stent allows only mechanical palliation of the obstruction, and has no anti-tumor effect. Currently, in the vascular field, the drug-eluting stent (DES) is very highly favored. Material and methods: The requirements for a DES in a non-vascular tract, such as the bile duct, are far different from those of a DES to be used in the vascular tract. The non-vascular DES must suppress tumor proliferation as well as mucosal hyperplasia. For example, the non-vascular stent might be covered with a membrane that gradually releases a chemo-agent. We do not have much experience with DES in the bile duct. Nonetheless, we are continuously testing many anti-tumor agents in animal and human studies. Conclusion: We expect and hope DES will work effectively for tumor cells in diverse ways and, more importantly, will prolong stent patency and the patients' survival periods. But considerable investigation and a clinical study of DES will be required to achieve these goals.",
author = "DongKi Lee",
year = "2009",
month = "6",
day = "25",
doi = "10.1007/s00534-009-0135-1",
language = "English",
volume = "16",
pages = "628--632",
journal = "Journal of Hepato-Biliary-Pancreatic Sciences",
issn = "1868-6974",
publisher = "Springer Verlag",
number = "5",

}

Drug-eluting stent in malignant biliary obstruction. / Lee, DongKi.

In: Journal of Hepato-Biliary-Pancreatic Surgery, Vol. 16, No. 5, 25.06.2009, p. 628-632.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Drug-eluting stent in malignant biliary obstruction

AU - Lee, DongKi

PY - 2009/6/25

Y1 - 2009/6/25

N2 - Introduction: In unresectable malignant bile duct obstruction, endoscopic stent insertion is the treatment of choice. However, the current stent allows only mechanical palliation of the obstruction, and has no anti-tumor effect. Currently, in the vascular field, the drug-eluting stent (DES) is very highly favored. Material and methods: The requirements for a DES in a non-vascular tract, such as the bile duct, are far different from those of a DES to be used in the vascular tract. The non-vascular DES must suppress tumor proliferation as well as mucosal hyperplasia. For example, the non-vascular stent might be covered with a membrane that gradually releases a chemo-agent. We do not have much experience with DES in the bile duct. Nonetheless, we are continuously testing many anti-tumor agents in animal and human studies. Conclusion: We expect and hope DES will work effectively for tumor cells in diverse ways and, more importantly, will prolong stent patency and the patients' survival periods. But considerable investigation and a clinical study of DES will be required to achieve these goals.

AB - Introduction: In unresectable malignant bile duct obstruction, endoscopic stent insertion is the treatment of choice. However, the current stent allows only mechanical palliation of the obstruction, and has no anti-tumor effect. Currently, in the vascular field, the drug-eluting stent (DES) is very highly favored. Material and methods: The requirements for a DES in a non-vascular tract, such as the bile duct, are far different from those of a DES to be used in the vascular tract. The non-vascular DES must suppress tumor proliferation as well as mucosal hyperplasia. For example, the non-vascular stent might be covered with a membrane that gradually releases a chemo-agent. We do not have much experience with DES in the bile duct. Nonetheless, we are continuously testing many anti-tumor agents in animal and human studies. Conclusion: We expect and hope DES will work effectively for tumor cells in diverse ways and, more importantly, will prolong stent patency and the patients' survival periods. But considerable investigation and a clinical study of DES will be required to achieve these goals.

UR - http://www.scopus.com/inward/record.url?scp=70049085839&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70049085839&partnerID=8YFLogxK

U2 - 10.1007/s00534-009-0135-1

DO - 10.1007/s00534-009-0135-1

M3 - Article

C2 - 19554255

AN - SCOPUS:70049085839

VL - 16

SP - 628

EP - 632

JO - Journal of Hepato-Biliary-Pancreatic Sciences

JF - Journal of Hepato-Biliary-Pancreatic Sciences

SN - 1868-6974

IS - 5

ER -